• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable NSCLC".

作者信息

Jiang Dongzhi, Yang Fei, Deng Huiwei

机构信息

Department of Anesthesiology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, People's Republic of China.

Department of Thoracic Surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, People's Republic of China.

出版信息

J Thorac Oncol. 2024 Dec;19(12):e79-e80. doi: 10.1016/j.jtho.2024.07.026.

DOI:10.1016/j.jtho.2024.07.026
PMID:39645302
Abstract
摘要

相似文献

1
Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable NSCLC".关于“在可切除非小细胞肺癌新辅助免疫检查点阻断随机对照试验中，评估主要病理反应和病理完全缓解作为生存替代终点”的评论
J Thorac Oncol. 2024 Dec;19(12):e79-e80. doi: 10.1016/j.jtho.2024.07.026.
2
Commentary on "Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC".关于“在可切除非小细胞肺癌新辅助免疫检查点阻断随机对照试验中，评估主要病理反应和病理完全缓解作为生存替代终点”的评论
J Thorac Oncol. 2024 Dec;19(12):e80-e81. doi: 10.1016/j.jtho.2024.09.1424.
3
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.评估新辅助免疫检查点阻断在可切除 NSCLC 中的随机对照试验中主要病理缓解和病理完全缓解作为生存替代终点。
J Thorac Oncol. 2024 Jul;19(7):1108-1116. doi: 10.1016/j.jtho.2024.03.010. Epub 2024 Mar 8.
4
Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.外科视角下的非小细胞肺癌新辅助免疫治疗。
Ann Thorac Surg. 2022 Oct;114(4):1505-1515. doi: 10.1016/j.athoracsur.2021.06.069. Epub 2021 Jul 30.
5
Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors.接受新辅助免疫检查点抑制剂治疗的非小细胞肺癌的病理反应和免疫生物标志物评估
Cancers (Basel). 2022 Jun 2;14(11):2775. doi: 10.3390/cancers14112775.
6
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives.可切除非小细胞肺癌（NSCLC）的新辅助免疫治疗策略：特殊人群中的现有证据和未来展望。
Cancer Treat Rev. 2024 Dec;131:102845. doi: 10.1016/j.ctrv.2024.102845. Epub 2024 Oct 16.
7
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.新辅助-辅助与新辅助单药 PD-1/PD-L1 抑制剂治疗可切除 NSCLC 患者的疗效比较：一项间接荟萃分析。
JAMA Netw Open. 2024 Mar 4;7(3):e241285. doi: 10.1001/jamanetworkopen.2024.1285.
8
Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.可切除非小细胞肺癌新辅助治疗中免疫治疗的现状和未来展望。
Asia Pac J Clin Oncol. 2022 Aug;18(4):335-343. doi: 10.1111/ajco.13665. Epub 2021 Nov 23.
9
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.可切除非小细胞肺癌新辅助免疫检查点抑制剂的新兴生物标志物
Transl Lung Cancer Res. 2021 Jan;10(1):590-606. doi: 10.21037/tlcr-20-573.
10
Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.新辅助 PD-(L)1 阻断联合铂类化疗治疗潜在可切除的驱动基因阳性非小细胞肺癌。
World J Surg Oncol. 2024 Jun 18;22(1):159. doi: 10.1186/s12957-024-03434-1.